Leap Therapeutics (LPTX) News Today $2.59 -0.11 (-4.07%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Buy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial OutlookNovember 15, 2024 | markets.businessinsider.comLeap Therapeutics Reports Q3 2024 Progress and FinancialsNovember 15, 2024 | markets.businessinsider.comSimplify Asset Management Inc. Grows Position in Leap Therapeutics, Inc. (NASDAQ:LPTX)Simplify Asset Management Inc. raised its stake in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 67.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,056,895 shares of the company's stock after buying anNovember 15, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.50 price target on shares of Leap Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comLeap Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | prnewswire.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Sees Significant Drop in Short InterestLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 723,500 shares, a decline of 19.5% from the September 30th total of 899,100 shares. Based on an average daily trading volume, of 149,100 shares, the short-interest ratio is presently 4.9 days. Approximately 2.4% of the shares of the stock are short sold.October 27, 2024 | marketbeat.comLeap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsSeptember 30, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Stock Crosses Below Fifty Day Moving Average of $2.58Leap Therapeutics (NASDAQ:LPTX) Shares Cross Below 50-Day Moving Average of $2.58September 28, 2024 | marketbeat.comSimplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)Simplify Asset Management Inc. increased its position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 67.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 631,269 shares of the compaSeptember 20, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest UpdateLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 1,230,000 shares, a growth of 17.1% from the July 31st total of 1,050,000 shares. Approximately 4.1% of the company's shares are sold short. Based on an average trading volume of 134,000 shares, the short-interest ratio is presently 9.2 days.August 31, 2024 | marketbeat.comLeap Therapeutics Inc (5MC.MU)August 23, 2024 | sg.finance.yahoo.com3 Trending Biotech Penny StocksAugust 22, 2024 | 247wallst.comVanguard Group Inc. Acquires 457,904 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)Vanguard Group Inc. boosted its holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 111.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 867,708 shares of the company's stock after acquirAugust 20, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short InterestLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 1,050,000 shares, a decline of 7.1% from the July 15th total of 1,130,000 shares. Approximately 3.5% of the company's stock are short sold. Based on an average daily trading volume, of 145,200 shares, the short-interest ratio is presently 7.2 days.August 19, 2024 | marketbeat.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | finanznachrichten.deQ3 2024 EPS Estimates for Leap Therapeutics, Inc. (NASDAQ:LPTX) Decreased by AnalystLeap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for Leap Therapeutics in a research note issued to investors on Tuesday, August 13th. HC Wainwright analyst S. Ramakanth now forecasts that the compAugust 15, 2024 | marketbeat.comMaintained Buy Rating for Leap Therapeutics Amid Promising Clinical and Financial OutlookAugust 14, 2024 | markets.businessinsider.comLeap Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Trading Down 4.3%Leap Therapeutics (NASDAQ:LPTX) Shares Down 4.3%June 7, 2024 | marketbeat.comBuy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic ExpansionMay 14, 2024 | markets.businessinsider.comLeap Therapeutics (NASDAQ:LPTX) Given New $5.50 Price Target at HC WainwrightHC Wainwright decreased their price target on shares of Leap Therapeutics from $7.00 to $5.50 and set a "buy" rating for the company in a research note on Tuesday.May 14, 2024 | marketbeat.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024May 13, 2024 | investorplace.comLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2024 Financial ResultsMay 13, 2024 | finanznachrichten.deLeap Therapeutics Reports First Quarter 2024 Financial ResultsMay 13, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Trading 0.6% Higher Leap Therapeutics (NASDAQ:LPTX) Trading Up 0.6%May 4, 2024 | marketbeat.comLeap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%April 11, 2024 | markets.businessinsider.comLeap Therapeutics Announces $40 Million Private PlacementApril 11, 2024 | prnewswire.com5 Best Biotech Penny Stocks to Invest InMarch 26, 2024 | insidermonkey.comQ1 2024 Earnings Estimate for Leap Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:LPTX)Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Leap Therapeutics in a report released on Tuesday, March 19th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.58)March 21, 2024 | marketbeat.comLeap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy RatingMarch 19, 2024 | markets.businessinsider.comLeap Therapeutics (NASDAQ:LPTX) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Leap Therapeutics in a report on Tuesday.March 19, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Price Target Cut to $9.00Robert W. Baird reduced their price target on shares of Leap Therapeutics from $11.00 to $9.00 and set an "outperform" rating on the stock in a research report on Tuesday.March 19, 2024 | marketbeat.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023March 18, 2024 | investorplace.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | finanznachrichten.deLeap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | finance.yahoo.comLPTX Apr 2024 5.000 callMarch 15, 2024 | finance.yahoo.comAcuta Capital Partners LLC Purchases New Shares in Leap Therapeutics, Inc. (NASDAQ:LPTX)Acuta Capital Partners LLC purchased a new stake in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 354,166 shares of the company's stock, valued at approximaMarch 3, 2024 | marketbeat.com683 Capital Management LLC Has $676,000 Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX)683 Capital Management LLC lifted its position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 60.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 490,000 shares of the compaMarch 1, 2024 | marketbeat.comLPTX Mar 2024 7.000 callFebruary 17, 2024 | finance.yahoo.comOutperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial OutcomesJanuary 26, 2024 | markets.businessinsider.comEvolus, Leap Therapeutics among healthcare moversJanuary 17, 2024 | msn.comLeap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumJanuary 16, 2024 | finance.yahoo.comOptimism High as Leap Therapeutics’ Studies Suggest Potential for Significant Shareholder ValueJanuary 6, 2024 | markets.businessinsider.comLPTX Jun 2024 1.000 callJanuary 4, 2024 | ca.finance.yahoo.comLPTX Mar 2024 1.000 callJanuary 4, 2024 | ca.finance.yahoo.comLeap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2024 | finance.yahoo.comLeap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsJanuary 2, 2024 | finance.yahoo.comLeap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumDecember 11, 2023 | finance.yahoo.comLeap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceNovember 21, 2023 | finance.yahoo.comRaymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To KnowNovember 14, 2023 | markets.businessinsider.com Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! LPTX Media Mentions By Week LPTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPTX News Sentiment▼1.240.45▲Average Medical News Sentiment LPTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPTX Articles This Week▼61▲LPTX Articles Average Week Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tonix Pharmaceuticals News ProPhase Labs News Mersana Therapeutics News Eton Pharmaceuticals News Poseida Therapeutics News Atea Pharmaceuticals News Atai Life Sciences News UroGen Pharma News Lifecore Biomedical News Atyr PHARMA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LPTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPTX Stock Alerts